Fellowship Program

OVERVIEW

The Emory University School of Medicine Pediatric Nephrology Fellowship Program capitalizes on the outstanding clinical and academic facilities of Emory University and Children’s Healthcare of Atlanta to prepare trainees for specialization in Pediatric Nephrology. We offer a 3 year curriculum that combines dynamic clinical service, structured didactics, and mentored clinical or basic research. Serving a catchment area with a population of over 10 million people, many of our clinical services are amongst the largest in the country, with large dialysis and kidney transplant programs. Our Divisional faculty of 11 pediatric nephrologists spans a broad spectrum of career experience, including junior, mid -career, and senior physicians comprising a wealth of experience and a lifelong dedication to teaching. Our goal is to train academically oriented pediatric nephrologists who will be involved in a lifetime of excellence in patient care, teaching, and research. The program is accredited by the Accreditation Council for Graduate Medical Education.
         
The Division provides clinical services at Children's Healthcare of Atlanta at Egleston, a 295 bed children’s hospital on the campus of Emory University .
Children’s is ranked as one of the top children’s hospitals nationwide. Our pediatric ESRD program serves some 30-50 chronic dialysis patients at a time and averages over 25 transplants per year. In fact, since 2007, our pediatric transplant service has ranked one or two in the country for the cumulative number of transplants performed. Some of the outstanding collaborative research opportunities within Emory include the transplant program, adult nephrology and the school of public health. Children's Healthcare of Atlanta offers state-of-the-art pediatric facilities and support, while Emory University provides beautiful campus surroundings and one of the nation's fastest research growth trajectories. Research funding for the Emory University School of Medicine Department of Pediatrics ranked #4 among 2017 NIH rankings of Departments of Pediatrics nationally.
lg Larry Greenbaum, MD, PhD
Professor
Division Director
lgreen6@emory.edu
db Donald Batisky, MD
Professor
Director, Pediatric Hypertension Program
dbatisk@emory.edu
lg Stella Shin, MD
Assistant Professor
stella.shin@emory.edu
db Rouba Garro, MD
Assistant Professor
Medical Director of Kidney Transplant
rouba.garro@emory.edu
lg Stephanie Jernigan, MD
Assistant Professor
Chief of Medicine Service Line
Medical Director of Dialysis
smjerni@emory.edu
db Chia-shi Wang, MD, MSc
Assistant Professor
chia-shi.wang@emory.edu
lg Roshan George, MD
Assistant Professor
Associate Pediatric Nephrology Fellowship Program Director
Director of Renal Transplant Transition Program
Director, Transplant Quality
roshan.punnoose.george@emory.edu
db Sabina Kennedy, MD
Assistant Professor
sabina.kennedy@emory.edu
lg Barry Warshaw, MD
Professor
Fellowship Program Director
bwarsha@emory.edu
db Pamela Winterberg, MD
Assistant Professor
pamela.d.winterberg@emory.edu
lg Loretta Reyes, MD
Assistant Professor
loretta.reyes@emory.edu
   
To apply for a Fellowship, please complete an application through the Electronic Residency Application System (ERAS).

In order to be considered, applicants must have completed an accredited three-year pediatric residency program from U.S. or Canadian Institution by the beginning of the Fellowship program.

A completed application file will include:

  1. Completed application submitted through ERAS
  2. Current curriculum vitae
  3. Personal statement (The personal statement should include a description of previous research and clinical experience, reason for interest in a Pediatric Nephrology Fellowship, and an indication of your career goals.)
  4. Three letters of reference. One letter should be from the Director of your Residency Training Program
  5. USMLE Steps 1, 2, and 3 Score Reports
  6. Official Medical School Transcript
  7. ECFMG Report, if applicable
  8. A recent photograph (optional)

Interviews are required and will be conducted from September through November. Applicant selection will be done through the National Resident Matching Program (NRMP).

Relevant dates for applicants for 2018 are as follows:
  • NRMP Rank Order List Opens: October 24, 2018
  • NRMP Rank Order List Closes: November 28, 2018
  • Match Day: December 12, 2018


neph
CURRICULUM

The first year of training is dedicated primarily to clinical activities and the second and third years primarily to research, comprising a total of 16 months clinical emphasis and 20 months research. Abundant didactic activities and conferences, as described below, including a formal histopathology course taken with the adult nephrology fellows, provide for a rich learning environment.

FIRST YEAR: The first year of the program is dedicated primarily to clinical training, comprising 10 months, with 2 months allocated to introduction to research. Clinical training includes assignments to the inpatient wards and involves experience managing a wide variety of patients assigned to the nephrology service with disorders such as new and relapsing nephrotic syndrome, acute and chronic glomerulonephritis, hypertension, acute and chronic renal failure, hemolytic-uremic syndrome, new renal transplant recipients and those experiencing complications, and both peritoneal and hemodialysis patients. Fellows learn skills including renal biopsy and ordering of dialysis. During inpatient ward assignments, fellows also provide consultation to other services including the ICU's (PICU, NICU, and CICU) and learn to manage all acute dialysis modalities (hemodialysis, PD, and a high volume of continuous renal replacement predominantly in the form of CVVH). Advanced knowledge of fluid and electrolyte management is taught during these inpatient and consult service rotations. Six weeks of the first year entails full time assignment to our pediatric-specific hemodialysis unit and peritoneal dialysis clinic, a partnership with DaVita Dialysis, wherein fellows have in-depth training in principles, literature, and application of dialysis as well as the opportunity for hands-on familiarity with hemodialysis & peritoneal dialysis equipment & techniques. Similarly, in the ICUs, fellows learn the details of CVVH and are afforded hands-on familiarity with CVVH equipment and setup.

Two months of the first year are dedicated to research orientation with initial opportunity for project selection. In addition, Fellows participate in formal department-wide fellowship courses in Research Fundamentals, Quality Improvement, and Medical Ethics.

SECOND YEAR: The second year begins with consecutive research months during which the fellow finalizes selection of research project(s) and mentor(s). Two months are dedicated to inpatient ward assignments, and additional time is allocated to a mixture of important clinical experiences including coursework with Dr. Charles O'Neill in the Emory Department of Medicine Division of Nephrology learning Ultrasound for the Nephrologist; this course is virtually unique in the country and one that numerous practicing nephrologists have taken with excellent reviews; observations in the Emory HLA lab and with our local organ procurement organization (Lifelink); and experience with our Pediatric Urology colleagues observing voiding dysfunction clinics, urodynamic studies, and other relevant activities. Second year fellows participate in a formal department-wide fellowship course in Teaching to Teach. During clinical assignments in the second and third years, the Fellow assumes increased responsibilities in the evaluation and care of patients and in teaching of pediatric residents and medical students.

THIRD YEAR: The third year of training is dedicated primarily to completion of research projects and writing related abstracts and manuscripts. Two months of this year are spent on the inpatient wards with advanced clinical responsibilities.

During the entire 3-year training period, fellows attend all section conferences and seminars plus they are afforded the responsibility to follow their own cohort of general Nephrology patients in a mentored Fellows¿ Continuity Clinic.

WEEKEND/NIGHT CALL: Fellows take weekend call averaging one weekend every fifth week throughout the 3 year training period. Weeknight call averages every fourth or fifth night. Night call is always taken from home. An attending pediatric nephrologist is always on call with the Fellow. Fellows on call round with the attending on the inpatient service during weekends and holidays. Fellows average at least 3 two-day weekends off every 4 weeks. If circumstances arise, the Fellow will be dismissed home from inpatient clinical responsibilities to conform to the 80 hour per week maximum, in keeping with ACGME guidelines. Fellows are entitled to 3 weeks of vacation per year that may be taken at any time during research or outpatient rotation months with approval of the Program Director.

ADVOCACY: Each fellow is given the opportunity to attend Camp Independence. Hosted by Children¿s Healthcare of Atlanta, Camp Independence is one of the oldest and largest camps in the country for children and adolescents who have been diagnosed with kidney disease, are on dialysis, or have received a solid organ transplant. Camp Independence is a week-long summer camp experience held at Camp Twin Lakes, a unique camp venue that provides year-round recreational, therapeutic and educational programs for children facing serious illnesses and life challenges. For more information about Camp Independence, go to www.choa.org/campindependence.

neph

Pediatric Nephrology Renal Pathology Conference

Frequency: Monthly

This is a case-based conference with case presentations by nephrology faculty and/or Fellows followed by presentation of histologic findings in a teaching format presented by our pediatric renal pathologists.


Practical Nephropathology for Nephrology Fellows:

This is an annual focused renal pathology course for Adult and Pediatric Nephrology Fellows conducted by Emory renal pathologist Dr. Brad Farris and colleagues. The course comprises 8 hours of didactic presentations and covers at least the following topics:

       Normal Histology of the Kidney
       Immune Mechanisms of Glomerular Pathology
       Minimal Change Disease-Focal Sclerosis
       Membranous Nephropathy
       Membranoproliferative Glomerulonephritis
       IgA Nephropathy
       Acute Post-Streptococcal Glomerulonephritis
       Crescentic Glomerulonephritis
       Lupus Nephritis
       Diabetic Nephropathy
       Amyloidosis
       Thrombotic Microangiopathy
       Renal Transplant Pathology


Pediatric Nephrology Journal Club

Frequency: Monthly

Fellows and faculty present and discuss recently published articles of importance.


Pediatric Nephrology Invitee Conference

Frequency: Monthly

Topics of nephrologic interest are selected to be presented by Divisional faculty, local faculty or Fellow invitees, or Pediatric Nephrology Fellows (once yearly in their 2nd and 3rd years).


Pediatric Nephrology Core Curriculum Course

Frequency: Monthly

Fellows and faculty present didactic reviews of the core topics in the fellowship curriculum. There are 33 topics that are covered during the 3 year fellowship. In addition, 10 core Orientation topics are presented in a concentrated fashion each year during the month of July.


Pediatric Departmental CPC Grand Rounds

Frequency: Weekly

Departmental CPC Grand Rounds are presented by a Pediatric Resident and moderated by a pediatric faculty member with audience interaction, followed by a didactic wrap-up of the case-in-point by a faculty member or Fellow. Nephrology Fellows are expected to provide the didactic discussion at least once during their 2nd or 3rd year.


Emory Transplant Conference

Frequency: Weekly from September through May

These are outstanding didactic conferences presented by local faculty and distinguished worldwide guest speakers.


Emory Adult Nephrology Grand Rounds

Frequency: Weekly

These are outstanding didactic conferences presented by local faculty and fellows and distinguished worldwide guest speakers.


Multidisciplinary Pediatric Renal Transplant Patient Care Conference

Frequency: Monthly

Chronic kidney disease patients undergoing evaluation for renal transplantation are discussed to identify issues affecting eligibility for or special needs regarding transplantation in participatory fashion by pediatric nephrology faculty, Fellows, transplant surgeons, transplant nurse coordinators, social workers, and others.


Research in Progress Seminar

Frequency: PRN

Fellows and faculty present proposed research projects, updates on ongoing research projects, or give practice presentations in preparation for scientific meetings.


Multidisciplinary Inpatient Care Rounds

Frequency: Daily (during in-patient rotations)

During inpatient coverage, the Fellow, under the close supervision of the pediatric nephrology attending, is responsible to coordinate care of inpatients and to involve team members in the discussion on daily rounds. Attendants include the pediatric resident (PL2 or PL3) on monthly assignment to the Nephrology service, medical students, transplant nurse coordinators, dialysis nurses, nurse practitioners, social workers, child-life specialist, nutritionist, pharmacist, transplant services chaplain, and case coordinator.


Multidisciplinary Patient Care Dialysis Conference

Frequency: Monthly

The plan of care for all pediatric hemodialysis and peritoneal dialysis patients is discussed, including medical management and preparation for kidney transplantation.

RESEARCH TRAINING

In addition to clinical training, fellows pursue mentored research across a wide variety of investigational choices. The area of concentration is selected based on the interest of the fellow who is responsible for designing, implementing, and completing a hypothesis-driven scholarly project under the guidance of a Scholarship Oversight Committee (SOC) of advisors and mentors. Fellows are encouraged, but are not required, to apply for and secure external funding for their research endeavors, and are expected to submit the results of their research for dissemination in appropriate scholarly venues.

All Emory first year fellows across the Department of Pediatrics participate in a focused introductory research course entitled Fellows Introduction to Research Training (FIRsT), directed by Dr. Inci Yildirim from our Division of Infectious Diseases and involving numerous Emory faculty teaching a wide spectrum of clinical research skills.  

A funded Masters of Science in Clinical Research (MSCR) degree program is available to selected fellows desiring the highest level of preparation for a career in clinical and/or translational research. (see: http://www.actsi.org/training/ms-in-clinical-research/index.html).

An excellent Biostatistics Core provides assistance with analytics and statistical methodology for the design and preparation of studies, grant proposals, and manuscripts. (See www.pedsresearch.org/research/cores/biostatistics-core/overview/)

Division of Nephrology Fellows and Faculty alike benefit from outstanding clinical research coordinator support, led by Margo Kamel, PhD and a team of 3 other coordinators.  This group provides support for an impressive divisional portfolio of single and multicenter clinical research projects (see: https://www.pediatrics.emory.edu/documents/divisions/nephrology/Pediatric_Nephrology_Research_Protocols_10-07-16.pdf).

Research opportunities are diverse and plentiful (see Historical list of fellows¿ projects below) and may include collaboration with investigators from other divisions, departments, or schools within Emory.

Primary Research projects completed, or underway, by Emory Pediatric Nephrology Fellows, and their Primary Mentors:

  • Jennifer Jackson MD (2007-10):  Urinary Chemokines CXCL9 and CXCL10 are Non-Invasive Markers of Renal Allograft Rejection and BK Viral Infection. Allan Kirk, MD, PhD, Dept of Surgery, Transplant Immunology
  • Raed Bou-Matar MD (2009-12: Protein Abundance of Urea Transporters and Aquaporin 2 Change Differently in Nephrotic Pair-fed vs. Non-pair-fed Rats. Janet Klein, PhD, Dept of Medicine, Nephrology.
  • Sandeep Riar MD (2009-12):  Restless Legs Syndrome: Severity, Iron Status & Inflammation in Pediatric Chronic Kidney Disease.  Larry Greenbaum MD, PhD, Division Director, Pediatric Nephrology
  • Roshan George MD (2010-13): T cell Senescence and Exhaustion in Pediatric Pre-Transplant Patients with Chronic Kidney Disease.  Allan Kirk, MD, PhD.  Dept of Surgery, Transplant Immunology
  • Shahid Nadeem MD (2011-14): ACE Fetopathy and A Randomized Study of Two Doses of Vitamin D in Children with CKD.  Larry Greenbaum, MD, PhD.  Division Director, Pediatric Nephrology
  • Chia-shi Wang MD (2012-15): Single Center Experience of Inpatient Healthcare Utilization Among Pediatric Patients with Nephrotic Syndrome.  Larry Greenbaum, MD, PhD.  Division Director, Pediatric Nephrology
  • Frank Ayestaran MD (2012-15): Perceived Appetite and Clinical Outcomes in Children with Chronic Kidney Disease.  Larry Greenbaum, MD, PhD.  Division Director, Pediatric Nephrology
  • Rima Zahr DO (2013-16): Renoprotection by Atorvastatin in Sickle Cell Disease and A Multicenter Study of Biopsy Findings and Clinical Outcomes in Children with Sickle Cell Disease.  David Archer, PhD.  Pediatric Hematology and Larry Greenbaum, MD, PhD. Division Director, Pediatric Nephrology
  • Alana Bozeman MD (2014-17): Profiling Metabolic Differences between Graft- vs. Pathogen-Elicited CD8+ T Cell Responses.  Mandy Ford, PhD, Dept of Surgery, Transplant Immunology
  • Loretta Reyes MD (2015- ): Role of Dysregulated Arginine Metabolism in Uremic Cardiomyopathy.  Claudia Morris, MD.  Pediatric Emergency Medicine.
  • K'joy Simms MD (2106- ): Perceptions of Patients with Polycystic Kidney Disease on the Risk for Affected Offspring.  Fred Rhabari, MD.  Dept of Medicine, Nephrology
  • Karie Mersha MD (2016- ): Transplant Outcomes of Young Adults Cared for at Adult vs Pediatric Transplant Centers.  Rachel Patzer, PhD, MPH.  Dept of Surgery, Transplant Outcomes Research Program

db PGY-6 Fellows
Karezhe Mersha, MD
Medical School: University of Maryland, Baltimore, MD
Residency: University of Maryland Medical Center, Baltimore, MD
lg PGY-6 Fellows
K¿joy Simms, MD
Medical School: University of the West Indies Faculty of Medical Sciences, Jamaica
Residency: Morehouse School of Medicine, Atlanta, GA
db PGY-5 Fellows
Jackson Londeree, DO
Medical School: Arizona College of Osteopathic Medicine of Midwestern University
Residency/Chief Residency: The University of Texas Dell Medical School. Austin, TX
lg PGY-5 Fellows
Catherine Park, MD
Medical School: Medical College of Georgia at Augusta University, Augusta, GA
Residency/Chief Residency: University of Tennessee Health Science Center, Memphis, TN
PGY-4 Fellows
Ali Annaim, MD, MPH
Medical School: University of North Carolina
Residency: Riley Children's Hospital, Indianapolis, Indiana
EMORY PEDIATRIC NEPHROLOGY OPEN PROTOCOLS 2018


1. An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients with Atypical Hemolytic-Uremic Syndrome (aHUS Registry) (Study Number: M11- 001)

Purpose: The registry is an observational, non-interventional, multi-center, multi-national, study that has been designed to capture safety and effectiveness data specific to the use of eculizumab in aHUS patients, as well as to compile data on the long term manifestations of TMA complications of aHUS. The registry will enroll aHUS patients treated not with eculizumab. It is anticipated that patients will be followed at least for 5 years. Data collected in the registry will be reported to the FDA and the EMA.

http://clinicaltrials.gov/ct2/show/NCT01522183

Recruitment status: open to enrollment

Sponsor: Alexion Pharmaceuticals

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Segun Adgeabo, BS


2. Chronic Kidney Disease in Children Prospective Cohort Study (CKiD III)

Purpose: This is an observational study of children with chronic kidney disease. The primary goals of this study are to determine the risk factors for decline in kidney function and to define how a progressive decline in kidney function impacts neurocognitive function and behavior; the risk factors for cardiovascular disease; and growth failure and its associated morbidity.

http://clinicaltrials.gov/ct/show/NCT00327860?order=1

Recruitment status: Enrolling

Sponsor: National Institute of Health (NIH)

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Segun Adgeabo, BS and Margo Kamel, PhD

3. Childhood Nephrotic Syndrome Observational Study (CNOS)

Purpose: Childhood onset nephrotic syndrome is a condition that affects the kidneys. It causes them to leak protein from the blood into the urine. The purpose of this study is to improve our understanding of the causes, effects, and treatment response of childhood nephrotic syndrome. We are also hoping to find out more information about how nephrotic syndrome progresses in different people and how or why that happens.

Recruitment status: Enrolling

Sponsor: Investigator Initiated

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Brian Lee, BS and Helina Iyob Tessema, BS

4. A Molecular Pathogenesis-Driven Approach for Diagnosis and Treatment of Complement-Based Renal Diseases (KidCOM)

Purpose: The purpose of this research is to build a registry of patients with aHUS and MPGN. MPGN is a rare disease that can cause problems with how the kidney filters blood and waste. Currently, little is known about how to treat MPGN. There are three different types of MPGN; MPGN I, MPGN II/Dense Deposit Disease (MPGN II/DDD), and MPGN III. Although we will look at all types of MPGN, we are focused on MPGN II/DDD because it is most closely linked to the immune system. Hemolytic Uremic Syndrome (HUS) is another rare immune disease that affects blood supply to the kidneys, and impairs their function. There are two types of HUS; typical HUS, and atypical HUS. Typical HUS, which is usually diagnosed in childhood, is due to a bacterial infection in the stomach and intestines. Atypical HUS (aHUS) is a hereditary disease that is associated with recurrent episodes.

Recruitment status: Enrolling

Collaborators: Dr. Christoph Licht at The Hospital for Sick Children, Toronto, Ontario, Canada; Dr. William Smoyer at The Research Institute at Nationwide Children's Hospital, Columbus, Ohio; Dr. Patrick Brophy at University of Iowa Hospitals and Clinics, Iowa City, Iowa.

Sponsors: Foundation for Children with Atypical HUS, and Optherion, Inc.

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Brian Lee, BS

5. Pediatric Lupus Nephritis Registry (Lupus Registry)

Purpose: This study will examine the incidence, causes, clinical course, and outcomes in children with lupus kidney disease. After informed consent and assent, medical records will be reviewed and history, physical exam findings, laboratory, radiology, hospital events, and medication information will be recorded into a multi-center registry. Longitudinal data will be collected for at least 5 years after entry into the registry.

Recruitment status: Enrolling

Participating site with Children¿s Hospital of Chicago

Site PI: Dr. Donald Batisky, Director of Hypertension Program, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Brian Lee, BS

6. Nephrotic Syndrome Study Network (NEPTUNE)

Purpose: The purpose of this study is to find markers of Nephrotic Syndrome (kidney disease with too much protein in the urine). We are particularly interested in diseases called Focal and Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), and Membranous Nephropathy (MN). By collecting health information and laboratory samples, our goal is to learn more about these kidney diseases and find better ways to prevent and treat people with these kidney diseases. http://clinicaltrials.gov/ct2/show/NCT01240564?

Recruitment status: Closed enrollment but continuing to follow patients

Sponsor: National Institutes of Health (NIH)-National Institute of Diabetes and Digestive and Kidney Disease (NIDDK)

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinators: Brian Lee, BS

7. A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms with Switchover, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change)

Purpose:The purpose of this study is evaluate if abatacept is effective and safe in decreasing the level of protein loss in the urine in patients with excessive loss of protein in the urine (nephrotic syndrome) due to either focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD). Candidates must have a prior kidney biopsy with either diagnosis. Another kidney biopsy will not be required as part of the study. Candidates must have failed or be intolerant of prior therapy for their kidney disease. The failed or intolerant therapy must include corticosteroids and at least one other drug. Candidates can be adults and children over the age of 6. Abatacept will be administered by venous infusion every 4 weeks.

https://clinicaltrials.gov/ct2/show/study/NCT02592798

Recruitment status: Enrolling

Sponsor: Bristol-Myers Squibb

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Brian Lee, BS

8. CureGN: Cure Glomerulonephropathy Network (CureGN)

Purpose: There are several different types of glomerular diseases, such as minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and immunoglobulin A nephropathy (IgAN). Over time, these diseases may cause kidney damage. These kidney diseases are rare and because of that, it is difficult for individual researchers to gather a large enough number of people to effectively study underlying causes, identify markers of disease, and identify and evaluate new therapies. The purpose of CureGN is to gather a group of patients with glomerular disease to create a source of information and blood and urine samples, so that researchers can easily and effectively study glomerular disease.

Recruitment Status: Enrolling

Sponsor: National Institute of Health (NIH)

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Margo Kamel, PhD and Helina Iyob Tessema, BS

9. LN Antibodies: Prospective Pediatric Lupus Nephritis Study

Purpose: This study will examine the ability of novel antibodies or other biomarkers to predict 1) findings on kidney biopsy, 2) disease progression, or 3) response to therapy in children with lupus nephritis (LN). The intent is to enroll subjects who have or will also enroll in the MWPNC¿s Pediatric LN Registry (however, involvement in the registry is not required). After obtaining informed consent and assent, medical records including history, exam findings, laboratory radiology and biopsy findings, treatment information, and outcomes will be prospectively reviewed and recorded. There are 2 levels of involvement for this study. The short term goal of this study will be to measure antibody titers against basement membrane (BM) antigens in the plasma and urine at onset of LN and again 6-mo into therapy. Results would be compared with the currently available clinical indicators of outcome and treatment response. The long-term goal of this study will be to establish a bio-repository of blood and urine samples (level 1) and kidney tissue (level 2) to assess the utility of additional autoantibodies or other biomarkers in MWPNC pediatric LN cohort, and to facilitate collaboration with larger efforts for biomarker identification in SLE that would otherwise not have access to pediatric samples.

Recruitment Status: Enrolling

Participating site with Midwest Pediatric Nephrology Consortium (MWPNC)

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Brian Lee, BS

10. Practice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome

Purpose: This study is a multi-center registry that collects information on children with childhood nephrotic syndrome who have been treated with a drug called ACTHar. ACTHar use in children is limited so a data registry will help guide medical decisions in the future and will help to design future research studies.

Recruitment Status: Enrolling

Sponsor: North American Pediatric Transplant Case Study

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Margo Kamel, PhD

11. cNeptune (Children¿s Nephrotic Syndrome Study Network)

Purpose: In response to a request for applications by the National Institutes of Health, Office of Rare Diseases (NIH, ORD) for the creation of Rare Disease Clinical Research Consortia, a number of affiliated universities joined together with The NephCure Foundation the NIDDK, the ORDR, and the University of Michigan in collaboration towards the establishment of a Nephrotic Syndrome (NS) Rare Diseases Clinical Research Consortium. Through this consortium the investigators hope to understand the fundamental biology of these rare diseases and aim to bank long-term observational data and corresponding biological specimens for researchers to access and further enrich.

Recruitment Status: Closed enrollment but to continue to follow patients

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Brian Lee, BS
https://clinicaltrials.gov/ct2/show/NCT01209000

12. Urological and Renal Disease Engaging Adolescents in Adherence Collaborative Trial (U-REAACT)

Purpose: The overarching goal of this five-year, phase II, randomized clinical trial is to improve poor long-term health outcomes in both adolescents and young adults (AYA) with either a kidney transplant (KT) or spina bifida (SB), respectively. More specifically, this study will focus on decreasing premature allograft loss in subjects with kidney transplant (KT) due to medication nonadherence and kidney damage in subjects with SB due to urinary non-continence. To achieve these goals, this study will implement a real-time feedback system, Way to Health (WTH), that will provide education and support, increase awareness and incentivize positive health behavior, in addition to standard of care. Further, this study will investigate the mechanisms of behavior change by examining the role of financial incentives, positive feedback and the relationship between the two. The study will compare two cohorts of KT and SB subjects, which will undergo varied levels of financial incentives and positive feedback. Data from KT and SB subjects will be analyzed jointly and separately. This innovative mobile health (mhealth) strategy will improve our current measures of adherence and increase our understanding of factors that influence adherence for two AYA populations, KT and SB subjects, respectively. The study will contribute novel insight to inform the design of future interventions targeting persistence of behavior change and can be used in other centers and for other chronic disease groups.

The study intervention will use the WTH web-based platform to support AYA with KT or SB as they navigate their daily treatment burdens. This will be achieved via bi-directional text messaging, including the sending of reminders and positive feedback by WTH and the messaging of pictures of medication or catheter in hand at time of treatment by the participant. This intervention will assess sustainability of this novel bi-directional messaging system and the impact of providing education and support, increasing awareness and incentivizing positive health behavior in real-time.

Recruitment Status: Enrolling

Sponsor: National Institute of Health (NIH) and Children¿s Hospital of Philadelphia (CHOP)

Site PI: Dr. Roshan George

Site Coordinator: Helina Iyob-Tessema, BS
https://clinicaltrials.gov/ct2/show/NCT03045276

13. A Phase 2/3 Trial of the the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome (CARDINAL)

Purpose: This international, multi-center, Phase 2/3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with Alport syndrome. The Phase 2 portion of the trial will be open-label and enroll up to 30 patients. The Phase 3 portion of the trial will be double-blind, randomized, placebo-controlled and will enroll up to 180 patients.

Recruitment Status: Enrolling

Sponsor: Reata Pharmaceuticals

Site PI: Dr. Greenbaum

Site Coordinator: Brian Lee, BS
https://clinicaltrials.gov/ct2/show/NCT03019185

14. Study of Weekly RG-012 Injections in Patients with Alport Syndrome (HERA)

Purpose: This will be a randomized, double-blind, placebo-controlled, multi-center, Phase 2 study conducted in subjects with Alport syndrome at multiple investigative centers.

Recruitment Status: Planning

Sponsor: Regulus Therapeutics Inc.

Site PI: Dr. Greenbaum

Site Coordinator: Brian Lee, BS
https://clinicaltrials.gov/ct2/show/NCT02855268

15. TRANQUIL Study: Transplant Recipient’s Adherence, Quality of Life and Outcomes In the context of Health Literacy

Purpose: The purpose of this study is to assess the association between health literacy, heath related quality of life, and long-term clinical outcome in kidney transplant recipients or patients preparing for a kidney transplant.

Recruitment Status: Enrolling

Sponsor: Investigator initiated

Site PI: Dr. Roshan George and Dr. Margo Kamel

16. UTOPIA: Urinary Biomarkers To Produce Improved Outcomes After Renal Transplantation

Purpose: The purpose of this study is to find out if a type of urine test can tell us how your kidney transplant is doing. We think that this urine test can help us determine if you are more likely to reject your kidney transplant.

Recruitment Status: Enrolling

Sponsor: Investigator initiated

Site PI: Dr. Roshan George

Site Coordinator: Brian Lee, BS

17. ACTH for Drug REsisitant Nephrotic Syndrome in ChiLdren (ADRENL)

Purpose: The purpose of this study is to use purified porcine Acthar Gel (ACTHAR, Mallinckrodt Pharmaceuticals) for treatment of SRNS in a prospective pilot study. The study will enroll 25 children between the ages of 2 to 21 years. Children fulfilling strict inclusion criteria, whose parents agree to written informed consent after institutional IRB approval for the study, will be enrolled. Purified porcine Acthar Gel will be administered SQ to all children using a defined treatment protocol for a period of six months. Renal function, urine protein excretion, serum albumin levels, blood pressure and growth parameters will be monitored closely on all patients. Baseline urine protein excretion will be compared to end of treatment levels to determine successful response to therapy. There will be an 18 month enrollment period, 6 month treatment period and a 12 month follow-up period.

Recruitment Status: Enrolling

Sponsor: Investigator initiated, M. Khurram Faizan, MD, FAAP, Hasbro Children’s Hospital, Providence, RI.

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Brian Lee, BS
https://clinicaltrials.gov/ct2/show/NCT03408405

18. Antibody Mediated Rejection Practice Patternes, Treatment Outcomes and Infection Rates

Purpose: The purpose of this study is to define the optimal therapy for AMR in chidren transplant populations.

Recruitment Status: No active recruitment. This is a retrospective chart review

Sponsor: Katherine Twombley, MD.

Site PI: Rouba Garro

Site Coordinator: Margo Kamel, PhD

19. A Phase 3 Multicenter, Randomized, Double-blinded, Placebo-controlled Withdrawl study Evaluating ADV7103 in Pediatric and Adult Subjects with Distal Renal Tubaar Acidosis (ARENA-2)

Purpose: This is a phase 3, prospective, multicenter, randomized, double-blinded, placebo-controlled, study product withdrawal study comparing the efficacy of ADV7103 versus placebo in preventing the development of metabolic acidosis defined by serum bicarbonate level in pediatric (6 months to <18 years of age) and adult (18 to 65 years of age) subjects with primary dRTA.

Recruitment Status: Enrolling

Sponsor: Advicenne Pharma

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Brian Lee
https://clinicaltrials.gov/ct2/show/NCT03644706

20. Ventricular Strain Analysis using Echocardiograms Obtained in the Chronic Kidney Disease in Children (CKID) Study – CKID Strain

Purpose: To evaluate early, subclinical myocardial dysfunction in children with CKD by analyzing echocardiographic images obtained during the CKiD study for myocardial strain and identify clinic determinates for changes in myocardial strain.

Recruitment Status: enrolling (retrospectively)

Sponsor: Investigator Initiated

Site PI: Dr. Pamela Winterberg

Site Coordinator: Margo Kamel, PhD

21. Cystinosis: Clinical Outcomes in a Contemporary Group of American Patients

Purpose: This is a multi-center retrospective study to define the clinical outcomes of a contemporary group of nephropathic cystinosis patients in the United States.

Recruitment Status: Enrolling (retrospectively)

Sponsor: Investigator Initiated: Horizon Pharma

Overall Study PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Margo Kamel, PhD

22. Natural History of Distal Renal Tubular Acidosis in a North American Cohort - dRTA

Purpose: To obtain data on the incidence of children with Distal Renal Tubular Acidosis (dRTA) as well as provide critical information on clinical outcomes and optimal therapy. This study is a multi-center retrospective chart review that will collect the following information from electronic medical records for analysis: basic demographics (age, race, gender, height, weight,) birth history, clinical presentation at the time of diagnosis, delay in diagnosis or misdiagnosis, method of diagnosis, growth history, treatment and complications with rickets, hearing loss, hypokalemia, nephrocalcinosis and kidney stones. Information about the therapy used to treat dRTA will also be collected. Data will be collected on the patients’ medical major history up to the date of data collection, consistent with the protocol (01/01/2000-12/31/2017).

Recruitment Status: Enrolling

Sponsor: Advicenne Pharmaceutical

Overall Study PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Margo Kamel, PhD

23. The US Registry for Fibromuscular Dysplasia - FMD

Purpose:The purpose of this study is to create a registry that will collect information about Fibromuscular Dysplasia (FMD).

Recruitment Status: Enrolling

Sponsor: Fibromuscular Dysplasia Society of American

Site PI: Sabina Kennedy, MD

Site Coordinator: Oluwasegun Adeagbo, BS

24. Grip Strength in Cystinosis

Purpose: The purpose of this study is to describe the severity of muscle weakness in patients with cystinosis.

Recruitment Status: Enrolling

Sponsor: Investigator Initiated

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Helina Iyob-Tessema, BS

25. Patterns of Acute and Chronic Kidney Injury in Children with Hypoplastic Left Heart Syndrome – (HLHS SVRIII)

Purpose: The purpose of this study is to determine factors affecting kidney outcomes following Single Ventricle Reconstruction.

Recruitment Status: Enrolling

Sponsor: SickKids

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Oluwasegun Adeagbo, BS

26. International Pediatric Peritoneal Dialysis Network – (IPPN)

Purpose: The purpose of this study is to have an open online registry to assess the mortality rate in children and adolescents on HD around the globe. Additionally, IPPN to monitor HD performance, hospitalization rates, growth and nutrition, and health related quality of life. The information collected will be used to revise ad implement worldwide clinical practice guidelines defining standards of pediatric HD care and to facilitate communication among pediatric HD specialist and to provide infrastructure for prospective trials.

Recruitment Status: Enrolling

Sponsor: Baxter Health Care, Fresenius Medical Care, ISPD

Site PI: Dr. Stephanie Jernigan

Site Coordinator: Margo Kamel, PhD

27. Improving Outcomes Collaborative – ( IROC)

Purpose: The Improving Renal Outcomes Collaborative is a network based learning health system of patients and families, clinicians, and researchers from the most advanced pediatric institutions in the country working together to solve difficult problems for children with kidney disease by sharing best practices and data about medical care and health outcomes, and applying quality improvement methods to improve health outcomes. The five key components of our collaborative include:

  • Focus on improving outcomes as our singular priority
  • Engagement of all stakeholders: patients, families, clinicians, researchers, existing networks
  • Culture of transparency, sharing and collaboration to accelerate dissemination and implementation of ideas that work
  • Effective use of technology to efficiently capture learning from the point of care, and create a learning health system
  • Seamless integration of research with clinical care; learn from every patient every day and implement research findings as they are generated
  • Core resources to train, mentor, and support centers in local quality improvement efforts and to facilitate the sharing and spread of ideas that work

Recruitment Status: Enrolling

Sponsor: CCHMC

Site PI: Dr. Rouba Garro

Site Coordinator: Margo Kamel, PhD, and Molly Parks, RN

28. Pediatric Kidney Disease Biorepository – (KiD-B)

Purpose: The purpose of the repository is provide biological samples for research projects addressing underlying mechanisms genetic determinants or predictive biomarkers.

Recruitment Status: Enrolling

Sponsor: Investigator Initiated- Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site PI: Pamela Winterberg

Site Coordinator: Brian Lee

29. A One arm, multi-center study to confirm the optimal starting dose of Mircera given subcutaneously for the maintenance treatment of anemia in pediatric patients with chronic kidney disease on peritoneal dialysis or not yet on dialysis

Purpose: To confirm the stating dose of Mircera given subcutaneously in pediatric patients with CKD on peritoneal Dialysis or not yet on dialysis when switching from stable subcutaneous maintenance treatment with epoeti alfa, epotetin beta, or darbepoetin alfa by demonstrating that Mircera administered subcutaneous maintains hemoglobin concentrations.

Recruitment Status: Enrolling

Sponsor: Hoffmann-La Roche Inc.

Site PI: Dr. Sabina Kennedy

Site Coordinator: Oluwasegun Adeagbo, BS
https://clinicaltrials.gov/ct2/show/study/NCT03552393

30. Maintenance therapy discontinuation of mycophenolate mofetil in pediatric lupus nephritis - MMF in Lupus

Purpose: The purpose of this research is to characterize renal outcomes in pediatric patients with proliferative and/or membranous lupus nephritis who are discontinued from maintenance mycophenolate mofetil (MMF) therapy.

Recruitment Status: Enrolling

Sponsor: Dr. Cynthia Silva, CCMC

Site PI: Catherine Park, MD

Site Coordinator: Oluwasegun Adeagbo, BS

31. Utility of Surveillance Biopsies in Pediatric Renal Transplant Recipients

Purpose: The purpose of this study is to describe histopathologic changes seen on surveillance biopsies and to assess whether the treatment of these biopsy findings affects allograft survival

Recruitment Status: Enrolling

Site PI: Rouba Garro, MD and Lorretta Reyes, MD

Site Coordinator: Margo Kamel, PhD

32. Reduction of Nephrotoxic Medication- associated Acute Kidney Injury in Children - NINJA

Purpose: The purpose of this study is to ensure children receive only the nephrotoxic medications they need for the time they need them.

Recruitment Status: Enrolling

Site PI: Stella Shin, MD

Site Coordinator: Margo Kamel, PhD

33. Chart Review: Post transplant diabetes in prior CHOA heart, Liver and kidney transplant patients- NODAT

Purpose: The purpose of this study is to determine the prevalence of diabetes among recipients of solid organ grafts at CHOA and determine the predictors of both post-transplant diabetes and remission of diabetes in recipients of solid organ grafts before age 18.

Recruitment Status: Enrolling

Sponsor: Mason Grant

Site PI: Rouba Garro, MD

Site Coordinator: Margo Kamel, PhD

34. Omentectomy and PD Catheter Revisions

Purpose: The purpose of this retrospective multi-center study is to determine the incidence of omentectomy at time of peritoneal catheter placement in incident pediatric ESRD-peritoneal dialysis patients.

Recruitment Status: Enrolling

Sponsor: Donna Claes, MD

Site PI: Stephanie Jernigan, MD

Site Coordinator: Margo Kamel, PhD

35. Effects of Physical Activity, Nutrition and Socioeconomic Status on Healthcare Utilization of Pediatric Post Kidney transplant Patients - PuSH UP

Purpose: The purpose of this study is to determine if an associations exist between the nutrition, physical activity, socioeconomic status and use of health care resources post-transplant of patients who have undergone kidney transplant surgery.

Recruitment Status: Enrolling

Sponsor: Investigator initiated

Site PI: Roshan George, MD and Margret Kamel, PhD

36. Changing the life of a Lupus patient one pamphlet at a time: Resource utilization and increase awareness on the quality of life in SLE patients: SUNDIAL

Purpose: This study aims to determine how awareness of SLE affects the quality of life of patients and effects or resource utilization post-diagnosis.

Recruitment Status: Enrolling

Sponsor: Investigator Initiated

Site PI: Roshan George, MD and Margret Kamel, PhD

37. Nephrotic Syndrome Manager Mobile Application- UrAPP

Purpose: The goal of this study is to develop a mobile app specific to NS with the capability of performing colorimetric analysis of urine protein results on dipsticks.

Recruitment Status: Enrolling

Sponsor: Pediatric Technology Center, Quick Wins

Site PI: Chia Shi Wang, MD

Site Coordinator: Margo Kamel, PhD

38. A phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Uremic Syndrome - aHUS 312

Purpose: The purposes of this study is to assess the efficacy of ALXN1210 in complement inhibitor treatment –naïve pediatric patients with aHUS to inhibit complement-mediated thrombotic microangiopathy (TMA) as characterized by thrombocytopenia, hemolysis and renal transplant

Recruitment Status: Enrolling

Sponsor: Alexion Pharmaceuticals, Inc

Site PI: Larry Greenbaum, MD

Site Coordinator: Segun Adeagbo, BS
https://clinicaltrials.gov/ct2/show/NCT01193348

39. An Open Label, Randomized, Active –controlle, Parrelle Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro) and Calcium Acetate (Phoslyra) in Pediatric and Adolscent CKD Patients with Hyperphostaemia. - Velphoro

Purpose: This a Phase 3, Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients with Hyperphosphataemia. The aim of this Phase 3 clinical study is to demonstrate similar efficacy of PA21 (Velphoro) in paediatric and adolescent patients with CKD, and to provide safety and dosing information for this patient population. The Phoslyra (comparator) group provides information for a descriptive comparison of PA21 against a commonly used calcium-based phosphate binder (calcium acetate).

Recruitment Status: Enrolling

Sponsor: Vifor Fresenius Medical Care Renal Pharma France

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Helina Iyob-Tessema, BS
https://clinicaltrials.gov/ct2/show/NCT02688764

40. Clinical Evaluation of PROMIS Pediatric Person-Reported Outcomes Measures in Children with Chronic Kidney Disease - CKID PEPR

Purpose: The purpose of this is study is to evaluate the clinical validity of a set of PROMIS pediatric person-reported outcome measures in patients with chronic kidney disease.

Recruitment Status: Enrolling

Sponsor: National Institutes of Health (NIH)

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Segun Adeagbo, BS

41. Retrospective Long-Term Follow-up of the CTOTC-02 Cohort; Immune Markers and Renal Transplant Outcomes in Children - CTOTC

Purpose: The purpose of this study is to determine the prevalence and risks factors for development of pre- and post- transplant AT1R-Ab in pediatric KTRs.

Recruitment Status: Enrolling

Sponsor: The National Kidney Foundation Young Investigator Grant

Site PI: Rouba Garro, MD

Site Coordinator: Segun Adeagbo, BS

42. The North American Pediatric Renal Transplant Cooperative Studies registry: NAPRTCS

Purpose: The purpose of this study is to enter data on care and treatment of pediactric renal disease and transplantation into a national registry. The data collected is expected to improve the medical care of children including those who have received renal transplants.

Recruitment Status: Enrolling

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Margo Kamel, PhD

43. Patient- derived endothelial cells to study the pathogenesis of microvascular disease - DGKE aHUS BOEC Mutation Registry

Purpose: The purpose of this research is to study and further understand a group of diseases known as microvascular disease and cystinosis.

Recruitment Status: Enrolling

Sponsor: SickKids

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Segun Adeagbo, BS

Children's Healthcare of Atlanta

Pediatric Nephrology Team Members

& Our Emory Transplant Surgery and Pediatric Urology Colleagues

Pediatric Nephrologists

Larry Greenbaum, MD, PhD, Division Director

Barry Warshaw, MD, Fellowship Program Director

Donald L. Batisky, MD

Stephanie Jernigan, MD

Pamela Winterberg, MD

Rouba Garro, MD

Roshan P. George, MD, Assoc. Fellowship Program Dir.

H. Stella Shin, MD

Chia-shi Wang, MD, MSc

Sabina Kennedy, MD

Loretta Reyes, MD

Pediatric Nephrology Fellows

Karezhe Mersha, M.D. - PGY-6

K'Joy Simms, MD - PGY-6

Jackson Londeree, DO - PGY-5

Catherine Park, MD - PGY-5

Ali Annaim, MD, MPH - PGY-4

Transplant Surgeons

Christian Larsen, MD, PhD

Thomas Pearson, MD, PhD

Kenneth Newell, MD, PhD

Paul Tso, MD

Nicole Turgeon, MD

Andrew Adams, MD, PhD

Ronald Parsons, MD

Idelberto ¿Raul¿ Badell, MD

Transplant Surgical Fellows

Jakub Woloszyn, MD, PhD

Siddarth Desai, MD

Octav Cristea, MD

Renal Transplant Coordinators

Debbie Stearns, BSN, CCTC

Kidney Transplant Ped. Nurse Practitioners

Rachel Mullis, DSN, PNP

Meredith Combs, MSN, CPNP

Taylor Thompson, MSN, PNP-AC, RN

Jennifer Tigner, CPNP/AC-PC

Chronic Renal Insufficiency Care Coordinators

Lynne Miles, BSN

Rhodina Bly, BSN, CPN

Nephrology Nurse Practitioners

Lindsay Armstrong, RN, CPNP

Caitlin White, RN, CPNP

Transplant Pharmacist

Rochelle Liverman, Pharm.D.

Staci Glumova, Pharm. D.

Nephrology Child Life Specialist

Ellie Armstrong

Nephrology Office Nurses

Vernon Griffith, LPN

Toni-Marie Partridge, RN

Carolyn Mitchell, RN

Lisa Palm, RN, MS

Jackie Steele, LPN – Clinic Nurse

Nephrology Office Administrative Assistant

Alicia Boswell – CHOA Clinics

Elizabeth (Liz) Shuler – Emory Academic

Nephrology Fellowship Program Coordinator

Mary Jane Polizzotto, BBA

Research Coordinators

Margret Kamel, PhD, MSPH, CCRC

Brian Lee, BS

Helina Iyob-Tessema, BS

Segun Adgeabo, BS

Transplant Services Administrator

Laura Williams, MBA, BSN, NE-BC

Transplant Services, CKD and HTN Manager

Lynn Sherrer, BSN, MN, PNP

Transplant Program Data Coordinator

Charlene Harris, BBA

Transplant Psychologist

Gloria Chaing, PhD

Nutritionist

Christine Benedetti

Pediatric Urology Colleagues

Emily Blum, MD

Wolfgang Cerwinka, MD

James Elmore, MD

Michael Louis Garcia-Roig, MD

Andrew Kirsch, MD

Hal Scherz, MD

Edwin Smith, MD

Pediatric Urology Fellows

Qiaqia Charlotte Wu, MD

Aylin Bilgutay, MD

Transplant Social Worker

Reva Bowers

CKD Clinic Social Worker

Reva Bowers

Transplant Services Educator

Dawn Johnson, BSN, RN,CPN,CCTN

Outpatient Educator ¿ Jennifer Ellison, RN


Atlanta, Georgia is a diverse, cosmopolitan, hospitable, tree-filled city of over 5 million people with seasonal climate suitable for nearly year-round outdoor activities. A major transportation hub, the city has long maintained a steady growth in both population and cultural diversity. While cost of living is lower than many other major cities, entertainment options are vast including college and professional sports, arts, museums, theaters, shopping, symphony, the world's largest aquarium, and innumerable restaurant options, including a wealth of ethnic cuisines.

Night Atlanta

The weather in Atlanta is mild, with average temperatures ranging in the 40's in winter to the 80's in summer. Winter may occasionally bring a light snow, and summer water activities can be comfortably enjoyed from May through September. The average annual rainfall in the Atlanta area is 48 inches.

Centennial Park

Centennial Olympic Park

Atlanta offers a wide range of outdoor recreational activities. Nearby lakes and rivers provide opportunities for fishing and swimming and just north of the city lie beautiful mountains that frequently draw those seeking trails for hiking and sites for camping. Atlanta is but a few hours away from the coastal communities and resorts of Georgia, Florida, South Carolina and Alabama.

Cultural activities in the city include a variety of theatres, art museums, symphonies, and historic sites such as the Carter Library and the Martin Luther King, Jr. Memorial. For the kid at heart, amusement parks, the Georgia Aquarium and Zoo Atlanta offer superb entertainment choices. The number of performing arts venues are almost too many to count. Atlanta is a sports lover's paradise, with competitive college athletics featured throughout the city and with the College Football Hall of Fame having recently relocated here. The city often hosts major sporting events such as the annual Southeastern Conference (SEC) football championship, the 2013 National Collegiate Athletic Association (NCAA) Men's Basketball Final Four competition and the 2013 NCAA Football Chick-Fil-A Bowl. Atlanta also offers a full range of enjoyable professional sports entertainment and venues with baseball, basketball, football and soon-to-be major league soccer teams each attracting loyal followings.

Atlanta truly is a place for everyone. It is a thriving, livable metroplex that strives to provide a comfortable, yet exciting place to call home.

Some Atlanta Links

Atlanta in 500 Words
Cost of Living Calculator

Civic:
About Atlanta
Access Atlanta
Atlanta.net
Atlanta Journal-Constitution
City of Atlanta

Attractions:
Atlanta Botanical Gardens
CNN Studio
Georgia Aquarium
Georgia State Parks & Historic Sites
Jimmy Carter Center
Martin Luther King, Jr. National Historic Site

Six Flags over Georgia
Six Flags White Water
Stone Mountain Park
World of Coca-Cola
Zoo Atlanta
Center for Civil and Human Rights
Atlanta History Center
College Football Hall of Fame


Sports:
Atlanta Braves
Atlanta Falcons 
Atlanta Golfer
 
Atlanta Hawks
 
Atlanta Motor Speedway
 


Cultural:
High Museum of Art
Atlanta Ballet
Atlanta Symphony
Alliance Theater

Other Places of Interest:
Ponce City Market
Krog Street Market


choa


Children's Healthcare of Atlanta, in collaboration with Emory University School of Medicine, offers three-year fellowships in pediatric nephrology to qualified, promising physicians. For more information please visit the CHOA Pediatric Nephrology Fellowship website.